The Daily Bolus: The Triple Agonist Showdown & Surprising GLP-1 Wins in Type 1 Diabetes
Welcome to today’s edition of The Daily Bolus! The incretin landscape is rapidly evolving into the era of the “triple agonist,” with Eli Lilly and […]
Month: March 2026
100% Insulin Independence: Why Eledon’s Breakthrough is a Pillar, Not a Cure
Eledon Pharmaceuticals recently achieved 100% insulin independence in an early-phase islet transplant trial using its anti-CD40L drug, tegoprubart. It’s a massive step forward in transplant immunology that avoids the toxicity of standard drugs. But why isn’t it a cure yet, and how does it fit into the actual blueprint of a functional cure?